Tpr-Met, the oncogenic counterpart of the Met receptor, has been detected in gastric cancers, as well as in precursor lesions and in the adjacent normal gastric mucosa. This has prompted the suggestion that Tpr-Met may predispose to the development of gastric tumors. Given the sequence specificity of RNA interference, oncogenes activated by point mutation or rearrangements can be targeted while spearing the product of the wild-type allele. In this work, we report specific suppression of Tpr-Met expression and inhibition of Tpr-Met-mediated transformation and tumorigenesis by means of a short interfering RNA (siRNA) directed toward the Tpr-Met junction (anti-TM2). When delivered by a lentiviral vector, anti-TM2 siRNA was effective also in mouse embryonal fibroblasts or epithelial cells expressing high levels of Tpr-Met. Our results suggest that lentiviral-mediated delivery of anti-TM2 siRNA may be developed into a powerful tool to treat Tpr-Met-positive cancers.
R
NA interference (RNAi) is a powerful physiological mechanism for sequence-specific, post-transcriptional gene silencing triggered by double-stranded RNA (dsRNA). 1, 2 In particular, the mediators of RNAi are small interfering RNAs (siRNAs), typically consisting of 21-to 23-nucleotide-long RNA duplexes with 2-to 4-nucleotide overhangs. Many reports have shown the efficacy and specificity of siRNA-mediated gene suppression in mammalian cells, obtained both via transfection of synthetic siRNAs and by using vectors where a short hairpin RNA (shRNA) is transcribed from a polymerase III-specific promoter. [3] [4] [5] [6] [7] ShRNA-expressing cassettes have been incorporated into retroviral and lentiviral vectors for more efficient delivery in primary and nondividing cells, or to generate transgenic mice. [8] [9] [10] [11] Recently, several inducible polymerase III promoters have been reported. [12] [13] [14] Met, a transmembrane tyrosine kinase, is the receptor for hepatocyte growth factor/scatter factor (HGF/SF). 15 Binding of HGF/SF to the Met receptor induces proliferation, motility and tubular morphogenesis in cultured cells. In vivo, HGF/SF and Met are essential for development, tissue regeneration and angiogenesis. Besides their physiological function, HGF/SF and Met have been shown to mediate malignant transformation. In response to HGF/SF stimulation, Met-expressing cells invade extracellular matrices and form metastatic tumors in nude and transgenic mice.
Met was originally cloned as the normal counterpart of an oncogene, Tpr-Met, derived from a chromosomal rearrangement. 16 Two leucine zippers in the Tpr moiety cause constitutive dimerization and sustained activation of the Met kinase domain. 17 The Tpr-Met translocation arose in a human osteosarcoma cell line after treatment with the chemical carcinogen N-methyl-N 0 -nitro-N-nitrosoguanidine (MNNG). 16 It has been shown that MNNG causes gastric cancer in monkeys. 18 Although not common in human tumors, Tpr-Met has been reported in gastric carcinomas. 19, 20 This suggests that MNNG or related carcinogens, present in trace amounts in food, Met can also be activated by mutation or overexpression. Numerous activating point mutations were discovered in the kinase domain of Met in all hereditary and most sporadic cases of papillary renal carcinoma, as well as in some cases of childhood hepatocellular carcinoma and of metastatic head and neck squamous cell carcinoma. 23 More recently, juxtamembrane point mutations have been identified in gastric and small cell lung cancer. 24, 25 Met is commonly found overexpressed in carcinomas and sarcomas, often in association with poor prognosis. Thus, Met is an important cancer gene, and can be considered one of the most attractive targets for innovative cancer therapy. 26 A number of approaches have been undertaken to inhibit Met, among which are truncated inactive forms of the ligand, neutralizing antibodies to HGF/SF, RNA/ ribozymes targeting HGF/SF and Met expression, and peptide substrate analogs. 27 The most direct way to inhibit the Met receptor is to target its kinase activity, and Met-directed inhibitors have recently been described. [28] [29] [30] However, since the role of HGF/SF and Met is not limited to embryogenesis but involves also organ regeneration, a Met inhibitor may cause side effects. Since RNAi allows to spare the product of the wild-type allele, when point mutations or a translocation are involved, it could be a preferable approach. 8 In this work, we show that Tpr-Met expression can be strongly and specifically suppressed by an shRNA covering the Tpr-Met junction (anti-TM2 shRNA). We have obtained stable Tpr-Met suppression in cultured cells delivering anti-TM2 shRNA by means of a modified selectable form of pSUPER and of a lentiviral vector adapted to express shRNAs. Anti-TM2 shRNA leads to loss of Tpr-Met-mediated transformation and tumorigenesis in cells overexpressing Tpr-Met. These results suggest that lentiviral-mediated delivery of anti-TM2 shRNA may be developed into a powerful tool to treat Tpr-Metpositive cancers.
Materials and methods

Reagents
All reagents, unless specified, were from Sigma Chemical Co.
Cells
NIH3T3 fibroblasts (a gift of Dr Gaudino, Amedeo Avogadro University, Novara), human embryo kidney 293 cells expressing SV40 large T antigen (293T cells), MEF Tet-Off and MDCK Tet-Off (from Clontech) were grown in DMEM (Euroclone) supplemented with 10% FBS (Euroclone) and were incubated at 371C in a 5% CO 2 -water-saturated atmosphere. NIH3T3-Tpr-Met cells (clone 8) have been previously described. 31 
Antibodies
The following antibodies were used: anti-human Met (C-12 #sc-10; Santa Cruz Biotechnology); anti-mouse Met 
Vectors construction
Tpr-Met-specific duplex shRNA oligos selected according to Elbashir et al 32 were introduced into pSUPER vector (OligoEngine). The fidelity of the inserts was verified by sequencing the region of interest. The 19-nucleotide sense strands of the specific oligos were: Tpr1 gtcctggagcgcacggagc; Tpr2 ttgctcaggatcgcaatat; Tpr3 gttccttgctgatcagcaa; TM1 cttgaatacttaacagatc; TM2 tacttaacagatcagtttc; Met1 gccgaaatgcgcccatcct; Met2 ctggtgtcccggatatcag; Met3 tactgcccagaccccttat; p53 shRNA control sequence was gactccagtggtaatctac. pSUPER-Blast vectors with control or TM2 shRNA sequences were generated by subcloning a blasticidin resistance cassette into the corresponding pSUPER vectors. pIRES-hrGFP-Tpr-Met and pBI-EGFP-Tpr-Met were generated by inserting the TprMet cDNA in pIRES-hrGFP-2a (Stratagene) and pBI-EGFP vectors (Clontech). pSUPER-Lenti transfer vector was generated by subcloning the H1RNA-promoter-TM2 shRNA cassette in pCCL.sin.PPT.hPGK. GFPWpre. 33 
Cell transfection
293T cells were cultured in six-well plates and transfected with the indicated plasmids using Lipofectamine 2000 (Invitrogen) following the manufacturer's protocol. NIH3T3-Tpr-Met cells, cultured in 100 mm diameter culture dishes, were transfected with pSUPER-Blast with control or TM2 shRNA sequences, selected with 5 mg/ml blasticidin for 30 days and collected for biochemical and cellular assays. MEF-Tpr-Met and MDCK-Tpr-Met were generated by transfecting MEF and MDCK Tet-Off cell lines with pBI-EGFP-Tpr-Met and a blasticidin selection plasmid. After selection in blasticidin, different resistant clones were picked and checked for Tpr-Met-inducible expression by Western blot.
Lentiviral vector production and in vitro transduction
High-titer lentiviral vector stock was produced in 293T cells by calcium phosphate-mediated transient transfection of the modified transfer and packaging vectors: pMDLg/pRRE, pRSV-Rev and pMD2.VSVG. The viral p24 antigen concentration was determined by HIV-1 p24 core profile ELISA (NEN, Life Science Product). MEFTpr-Met and MDCK-Tpr-Met cells (1 Â 10 5 cells in 35 mm diameter culture dishes) were transduced with 300 ng p24 of lentiviral vector in the presence of doxycycline (1 mg/ml) and polybrene (8 mg/ml).
Western blot analysis
Cells were washed with ice-cold PBS, lysed and scraped in lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 1 mM bglycerolphosphate) with protease inhibitors cocktail and 1 mM sodium orthovanadate. Protein lysates were cleared of cellular debris by centrifugation at 41C for 10 minutes at 12,000 g, resolved in 10% SDS-PAGE gels and transferred to Hybond-C Extra nitrocellulose membranes (Amersham Biosciences). Proteins were visualized with horseradish peroxidase-conjugated secondary antibodies and Super Signal West Pico Chemiluminescent Substrate (Pierce).
Cell proliferation assay
Cells were seeded in six-well plates at a density of 2 Â 10 4 cells/well. After 48 hours, cells were trypsinized and resuspended in PBS. Cell viability was assessed by Trypan blue exclusion and cells were counted in a Burker's hemocytometer chamber.
Anchorage-independent cell growth assay Cells were suspended in 0.35% agar in DMEM 10% FBS at 5 Â 10 4 cells/well and plated on a layer of 0.7% agar in complete medium in six-well culture plates and cultured at 371C with 5% CO 2 . After 4 weeks, colonies 4100 mm in diameter were counted.
In vitro invasion assay
Invasiveness was examined by using the membrane invasion culture system (transwell membranes of 6.5 mm diameter and 8 mm pore size; Costar) according to the standard protocol. Briefly, 10 5 cells were seeded onto the upper well of transwells previously coated with 50 ml of Matrigel Basement Membrane Matrix (Becton Dickinson). After 48 hours, the noninvasive cells on the upper surface of the membrane were removed with a cotton swab. The transformed cells that migrated through the Matrigel matrix and stuck to the lower surface of the membrane were fixed with 11% glutaraldehyde, stained with cresyl violet and photographed.
Scatter assay
Cells were seeded in six-well plates at a density of 5 Â 10 4 cells/well. Pictures were taken after 12 hours.
In vivo tumorigenesis assay
Cells were trypsinized and resuspended at 10 7 cells/ml in sterile PBS. Cells (1 Â 10 6 ) were injected subcutaneously (s.c.) into the flank of female nu/nu mice (n ¼ 6 mice/ group; Charles River). Tumor dimensions were measured with Vernier calibers every 3 days, and tumor volumes were calculated as the volume of a sphere.
Results
Identification of a specific and efficient shRNA sequence against the Tpr-Met oncogene To identify the shRNA sequence capable of suppressing Tpr-Met expression, we produced several constructs using the pSUPER plasmid, including sequences specific for different regions of Tpr-Met (Tpr1, Tpr2, Tpr3, specific for Tpr; TM1, TM2, specific for the Tpr-Met junction; Met1, Met2, Met3, specific for Met; Fig 1a) .
To test the efficacy and the specificity of the selected sequences, we cotransfected in 293T cells a fixed amount of a dicistronic plasmid expressing Tpr-Met and hrGFP (humanized Renilla reniformis green fluorescent protein (hrGFP)) from a single transcript with increasing amounts of the pSUPER constructs. PSUPER-TM2 was already effective in suppressing Tpr-Met by 24 hours from cotransfection, as inferred from the strong reduction of hrGFP fluorescence observed (Fig 1b) . Cells were lysed 60 hours after transfection and protein extracts were analyzed by Western blot. While all other constructs were without effect, pSUPER-TM2 abrogated Tpr-Met expression almost completely even at the lowest concentration (Fig 1c) . The silencing effect of pSUPER-TM2 was specific, as indicated by the fact that the pSUPER Tpr-Met-directed RNAi R Taulli et al construct with an unrelated sequence was without effect on Tpr-Met expression (Fig 1c) . Furthermore, none of the pSUPER constructs affected expression of b-actin or of endogenous full-size Met (Fig 1c) .
Expression of anti-TM2 shRNA in Tpr-Met-transformed NIH3T3 cells induces stable Tpr-Met suppression, phenotypic reversion and inhibition of proliferation and invasiveness
We generated a selectable form of pSUPER (pSUPERBlast) by subcloning the blasticidine resistance gene in the pSUPER vector. We verified the efficiency of this new silencing vector by cotransfecting pSUPERBlast-TM2 and the dicistronic pIRES-Tpr-Met-hrGFP plasmid in 293T cells. As judged by Western blot, Tpr-Met suppression was comparable to that obtained using pSUPER-TM2 (data not shown). To assess the effects of stably knocking down Tpr-Met, we transfected pSUPER-Blast-TM2 or an unrelated control sequence in Tpr-Met-transformed NIH3T3 cells (clone 8). Anti-TM2 shRNA induced in resistant cells a stable reduction of Tpr-Met expression, and a decrease in MAPK and Akt phosphorylation, while in cells expressing the control shRNA there was no alteration in the level of Tpr-Met and in the activation of downstream pathways (Fig 2a) . Furthermore anti-TM2 shRNA did not induce aspecific downregulation of endogenous genes such as b-actin, p65 NF-kB and mouse Met (Fig 2a) . Stable Tpr-Met suppression induced evident morphological changes in transformed NIH3T3 cells, which became flatter and larger than controls (Fig 2b) . Furthermore, the proliferation rate of NIH3T3-Tpr-Met cells stably expressing anti-TM2 shRNA was strongly reduced with respect to that of control cells (Fig 2c) . The invasive properties of NIH3T3-Tpr-Met cells stably expressing anti-TM2 shRNA or the control shRNA were also analyzed. While control Tpr-Mettransformed NIH3T3 migrated through a Matrigelcoated transwell polycarbonate membrane, the anti-TM2 shRNA-expressing cells did not cross the Matrigel barrier (Fig 2d) .
Expression of anti-TM2 shRNA suppresses Tpr-Metmediated anchorage independence and tumorigenicity in vivo
Tpr-Met-transformed cells are anchorage-independent and form tumors if transplanted in immunocompromised mice. We first tested the ability of NIH3T3-Tpr-Met cells stably expressing anti-TM2 shRNA (NIH-Tpr-Met TM2) to form anchorage-independent colonies. Anti-TM2 shRNA expression strongly reduced the number of colonies in soft agar compared to the untreated cells (NIH-Tpr-Met) and to the cells expressing the unrelated shRNA (NIH-Tpr-Met control) (Fig 3a) . NIH-Tpr-Met, NIH-Tpr-Met control and NIH-Tpr-Met TM2 cells were injected s.c. into nude mice, and tumor growth was measured weekly. At 2 weeks after the injection, the tumors originating from NIH-Tpr-Met and NIH-Tpr- Tpr-Met-directed RNAi R Taulli et al Met control cells were measurable. At 5 weeks, the animals were killed for ethical reasons given the tumor volume. On the contrary, at this time, in the animals injected with NIH-Tpr-Met expressing anti-TM2 shRNA, there was no detectable tumor mass (Fig 3b) . The success of a translocation-directed anticancer treatment will depend on the extent of suppression of the chimeric RNA and protein. We thus verified the potency of the anti-TM2 shRNA in mouse embryonal fibroblasts (MEF-Tpr-Met) expressing a level of Tpr-Met protein much higher than the NIH3T3 clone 8 described before (Fig 4a) . In MEF-Tpr-Met, expression of the Tpr-Met oncogene is controlled by a doxycycline-regulatable promoter. Transfection of pSUPER-Blast-TM2 was insufficient to stably suppress Tpr-Met expression in fully induced cells (data not shown). We thus introduced the pSUPER-TM2 cassette in a lentiviral vector with GFP as a reporter (Lenti-TM2). 33 We first tested Tpr-Met silencing in MEF-Tpr-Met cells as a function of the viral titer, using the viral protein p24 to quantify the virus. At 7 days postinfection, cells were subjected to GFP-directed FACS analysis to determine the efficacy of infection at different p24 values. p24 at 10 ng was capable of infecting 99% of the MEF-Tpr-Met cells, but a strong reduction of Tpr-Met expression was observed by Western blot only at 200 ng of p24 (data not shown).
Lentiviral transduction of MEF-Tpr-Met cells with anti-TM2 shRNA induces stable Tpr-Met suppression, morphological changes and inhibition of proliferation and invasiveness Stable Tpr-Met silencing was obtained by infecting MEFTpr-Met cells with 300 ng of Lenti-TM2 p24 (Fig 4b) . In these cells, we also observed a strong inhibition of MAPK and Akt phosphorylation, with no aspecific downregulation of endogenous genes such as b-actin, p65 NF-kB and mouse Met (Fig 4b) . Stable Tpr-Met suppression induced in these cells morphological changes (Fig 4c) and a reduction in proliferation rate (Fig 4d) and invasiveness (Fig 4e) .
Lentiviral transduction of MDCK-Tpr-Met cells with anti-TM2 shRNA inhibits Tpr-Met-mediated scatter
One of the biological effects of HGF in epithelial cells is the induction of motility. MDCK cells exposed to HGF dissociate from each other and disperse through the culture dish. 34 We generated stable MDCK cell lines expressing high levels of Tpr-Met in a doxycyclineregulatable way. When induced, these cells show a constitutively scattered phenotype (Fig 5a) . Infection of MDCK-Tpr-Met cells with high-titer Lenti-TM2 inhibited Tpr-Met expression and signaling (Fig 5b) , as well as cell scatter (Fig 5c) . On the other hand, the lack of signs of cellular stress, such as apoptosis or reduction of the proliferation rate, suggests that high-titer Lenti-TM2 did not induce important off-target effects in the infected MDCK-Tpr-Met cells. Furthermore, cytofluorimetric analysis showed that a high titer of Lenti-TM2 did not induce cell cycle alterations in naive MDCK and MEF cells (data not shown), indicating that high expression of anti-TM2 shRNA does not in itself cause aspecific growth arrest.
Discussion
Cancer is characterized by a progressive acquisition of genetic mutations. However, causal genetic lesions are known only for a limited number of malignancies, such as Bcr-Abl in chronic myeloid leukemia (CML) or c-Kit in GIST. Inhibition of these pathways may lead to a successful cancer treatment; the efficacy of Gleevec in these malignancies proves this concept. 35, 36 Interestingly, the Bcr-Abl rearrangement has been detected at low frequency also in healthy controls. 37 This suggests that Bcr-Abl is an early mutation in CML and that additional hits are necessary for the development of the disease. Importantly, however, Bcr-Abl remains necessary for the maintenance of this cancer. A similar situation may also apply to the case of gastric carcinoma and the Tpr-Met Tpr-Met-directed RNAi R Taulli et al rearrangement, which produces an oncogenic form of the Met receptor. Tpr-Met has been found in some cases of gastric cancers as well as in precursor lesions and in the adjacent healthy gastric mucosa. 19, 20 This suggests that Tpr-Met may be involved at an early stage of tumorigenesis and remain necessary for gastric tumor maintenance. Thus, Tpr-Met-directed silencing strategies may have therapeutic value.
Several recent reports suggest that RNAi can be applied to cancer therapy. SiRNAs against K-RAS V12 , H-ras, Bcr-Abl, B-RAF V599E , VEGF and cyclin E efficiently suppressed the transforming ability of these oncogenes in vitro and in vivo. 8, [38] [39] [40] [41] [42] In this study, we describe a TprMet-directed shRNA (TM2) that can be used to suppress efficiently Tpr-Met-mediated transformation in vitro and in vivo. Specific downregulation of Tpr-Met expression in stable cell lines caused inhibition of downstream signaling, which was accompanied by phenotypic changes and by reduction of proliferation. The ability of these cells to scatter, to invade a Matrigel barrier and to grow in soft agar was also impaired. Finally, these cells no longer formed tumors in vivo. It should be noted that while the plasmid-based shRNA-TM2-expressing vectors efficiently suppressed Tpr-Met expression in transient cotransfection, these vectors were ineffective in suppressing Tpr-Met in cell lines overexpressing the oncogene.
Different kinds of cancer are characterized by overexpression of tyrosine kinase receptors or of other oncogene products; thus, a successful therapeutic approach must ensure suppression of high level of aberrant protein. Our results indicate that lentiviral vectors could be the most effective when a high dosage of shRNA is required. Lentiviral vectors stably integrate into the chromosomes of their target cells and induce long-term transgene expression. Furthermore, the high efficiency of lentiviral gene transduction can compensate for the silencing of shRNAs-specific promoters that occurs upon integration in the host genome. However, our data indicate that Tpr-Met expression is only slightly downregulated after infection with low viral titers (even when 99% of the cells were transduced) and that efficient downregulation requires the use of high lentiviral titers.
These results highlight the potential of RNAi for the treatment of cancers where specific dominant genetic lesions have been identified. The specificity of the RNAi process, as seen for the Tpr-Met translocation, allows for the selective suppression of the oncogenic and not of the wild-type gene product. Third-generation lentiviral vectors could represent the most efficient way to deliver therapeutic shRNAs directly into primary tumors in the near future. The advantage of this tool with respect to the administration of synthetic siRNAs is that the latter require to be modified to promote stability and facilitate delivery in vivo. Furthermore, siRNAs as therapeutic drugs would require chronic administration, which can be avoided by a stable expression system. Both approaches represent a new class of genetic ''smart'' drugs directed against key dominant oncogenes to which the cancer is ''addicted''. 43 The development of such drugs is particularly desirable in the case of kinases, considering that siRNAs could to be used in combination with small molecule inhibitors to minimize resistance, which is the unavoidable consequence of the use of single highly specific agents.
